The ADC field is in a transitional period. Older approaches to conjugate composition and dosing regimens still dominate the ADC clinical pipeline, but preclinical work is driving a rapid evolution in how we strategize to improve efficacy and reduce toxicity towards better therapeutic outcomes. In an indication of future directions for the field, antibody conjugates bearing non-cytotoxic small molecule payloads are being developed to reduce side effects associated with treatment of chronic diseases.
Bioprocessing development is a long and costly process. Building in continuous characterization and connected bioprocessing cuts timelines and increases the available information through real-time analytics.
Understand the strategies which can be employed at the different stages of development when choosing parenteral dosage forms.
The extensive timeline to develop a drug is due to a multitude of formulation challenges that formulation experts face. When it comes to solving these challenges, there have been significant advancements in drug development techniques to counter these challenges including bioavailability, stability, efficacy, manufacturability, and safety.
Why understanding both the product and every step of the process is crucial in cell and gene therapy production.
Learn how a structured 3-step approach can help overcome the challenge of molecular characterization and a limited budget.
How SYLOID FP silica products contribute significantly in mitigating/resolving key challenges such as formulation stability over time and their ability to withstand challenging processing conditions.
The combined adsorption capacity, porosity, particle size, and density of the SYLOID® XDP silicas provide a tool to convert liquid ingredients into free flowing powder.
Grace’s SYLOID® 244 FP silica is highly porous and an excellent solution for converting viscous Simethicone into compressible free flowing powder to make chewable tablets.
SYLOID® FP and XDP silicas excipients are micronized synthetic amorphous silica gels of high purity which are widely formulated into many pharmaceutical products.
Considering that 90% of drug candidates have bioavailability issues, making sure your program is prepared for all phases of clinical trials from the very start is the fast way forward. Patheon Solubility Enhancement Services approaches BCS II and IV drug substance solubility issues a fundamentally different way that identifies the solubility enhancement technologies most likely to work before you get started. That helps eliminate rework and worry later on.
NuAire is pleased to partner with the reputable brand Hitachi Koki to offer our customers sales and support of table top and floor standing Mirco Ultracentrifuges in the North American market.
Our SYLOID® FP silica (silicon dioxide) has been widely used and trusted for decades by the pharmaceutical industry as an excipient and processing aid. The material's unique mesoporosity, adsorptive capacity, density, and greater internal surface area provide advantages over fumed silica (colloidal silicon dioxide) and offer multi-functional benefits to formulators. SYLOID® FP silica grades are engineered to deliver a range of properties and can act as an effective stabilizer, protectant, desiccant, disintegrant, anti-tacking, and/or anti-caking agent. Advanced applications such as oil adsorption, carrier, and liqui-solid can be achieved with SYLOID® XDP silica. Additionally, Grace offers SYLOID® G silica specifically designed for cost effective glidant in generic pharmaceutical formulations. All of Grace's SYLOID® silica products are a synthetic amorphous non-crystalline form.
High-quality API via the development of a scalable process that will meet demand at each stage of your product’s life cycle. Complete drug product services from preformulation screening through clinical development to commercial supply. A comprehensive range of oral solid, sterile and softgel dosage forms with expertise in high-potency products. Unique solutions to overcome the toughest solubility challenges and accelerate your path to proof of concept.
The Hitachi Koki model himac CR22N High-Speed Refrigerated Centrifuge offers reliable performance with a maximum RCF of 55,200xg and capacity of 6L for bottles, tubes, or microplates. Patented features such as the Automatic Rotor Identification and Rotor Cover Detector make the CR22N the ideal separation tool for multiple research applications involving DNA, RNA, viruses, proteins, and more.
DAVISIL® silica's chemical and structural properties are optimized for chromatographic performance. Tight control of these properties from raw material to finished product in addition to real time monitoring of production processes distinguishes DAVISIL® silica and ensures consistent performance.
Grace’s SILSOL® Silica-based Drug Delivery Technology was engineered to bring together advanced silica technologies with challenging active pharmaceutical ingredients (APIs) to help more effectively formulate a large class of poorly soluble but otherwise promising compounds.
NuAire benchtop centrifuges offer mono and multi functionality, refrigerated and non-refrigerated models. Technical innovations optimize productivity in your laboratory work to improve results, save time, while providing a greater relative centrifugal force (RFC).
